Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Pain Measurement
Interventions: Alfentanil, Propranolol, Placebo; Drug
Lead sponsor: Martin Angst; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Fever, Labor Pain, Complication of Anesthesia During Pregnancy, Unspecified
Interventions: Methylprednisolone, Normal saline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Euglycemia, Hypoglycemia, Hyperglycemia
Interventions: Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hemodialysis Complication, Hemodynamic Instability
Interventions: Mannitol, 0.9% saline; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Ficlatuzumab, Cetuximab, Placebo; Biological · Other
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more

Conditions: Surgical Incision, Pain, Postoperative, Pain, Acute
Interventions: Bupivacaine 0.25%, Normal Saline; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 2 Diabetes Mellitus, Bone Remodeling
Interventions: exenatide, Saline; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 45 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Type 1 Diabetes (T1D)
Interventions: Golimumab, Placebo (matching golimumab); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 44 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
Interventions: Bortezomib, Placebo, Mycophenolate mofetil; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Clostridium Difficile Infection
Interventions: Clostridium difficile vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 17,535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 220
States / cities: Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more

Conditions: Chronic Low-back Pain
Interventions: Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT); Other · Drug · Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Nashville, Tennessee

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1189, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 10 Years to 30 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 65
States / cities: Huntsville, Alabama • Anaheim, California • Colton, California + 56 more

Conditions: Warts
Interventions: Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline; Biological · Other
Lead sponsor: Western Institute for Veterans Research; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Necrotizing Soft Tissue Infections
Interventions: AB103, Placebo; Drug
Lead sponsor: Atox Bio Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 4 more

Conditions: Anemia
Interventions: VIT-45, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Pediatric Cancer, Thrombocytopenia, Hemostatic Disorder, Coagulation Defect; Acquired
Interventions: Tranexamic Acid, Normal saline; Drug
Lead sponsor: Meghan McCormick; Other
Eligibility: 2 Years to 21 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Respiratory Distress Syndrome, Adult
Interventions: BIO-11006, Placebo; Drug
Lead sponsor: BioMarck Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Chicago, Illinois • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Osteoarthritis
Interventions: onabotulinumtoxinA, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Artesia, California

Conditions: Healthy Participants, Non-cystic Fibrosis Bronchiectasis
Interventions: Rev-56 for Inhalation, Placebo: Normal saline; Combination Product · Drug
Lead sponsor: Revagenix, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: GLP-1, GIP; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: NasoShield, BioThrax, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Melbourne, Florida • San Antonio, Texas

Conditions: Osteoporosis
Interventions: Calcium Chloride/Calcium Gluconate, Half-Normal Saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years to 80 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Inhaled iloprost 5.0 mcg, Placebo; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Thyroidectomy, Nerve Monitoring
Interventions: Lidocaine, Placebo; Drug
Lead sponsor: Bronx-Lebanon Hospital Center Health Care System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Evaluation of Propranolol's Effect on Pain and Inflammation.

Maternal Epidural Steroids and Hyperthemia

Intravenous Exenatide (Byetta) During Surgery

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Continuous Erector Spinae Plane Blocks to Treat Postoperative Pain After Open Gynecologic Procedures Via a Low Transverse (Pfannenstiel) Incision

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

Clostridium Difficile Vaccine Efficacy Trial

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia

A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NasoShield Study of Safety and Immunogenicity

PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)

Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring